Spero Therapeutics, Inc. (SPRO )

Currency in USD Disclaimer
$2.88 +$0.38 (15.2%)
Open 06/02/2025
$2.42
$2.95
$0.51
$2.48

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol SPRO
  • Company Spero Therapeutics, Inc.
  • Price $2.88
  • Changes Percentage 15.2
  • Change 0.38
  • Day Low $2.42
  • Day High $2.95
  • Year High $2.48
  • Year Low $0.51
  • Market Cap $119,089,578
  • Price Avg 50 EMA (D) $0.75
  • Price Avg 200 EMA (D) $1.02
  • Exchange NASDAQ
  • Volume 7,256,121
  • Average Volume 3,204,917
  • Open $2.51
  • Previous Close $2.5
  • EPS -1.28
  • PE -1.66
  • Earnings Announcement 2025-08-04 10:59:00
  • Shares Outstanding $55,910,600

Company brief: SPERO THERAPEUTICS, INC. (SPRO )

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

SPRO Corporation News

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

May 29, 2025 at 4:21 pm ET

zacks.com -- SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options....

Income Statement